Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 11/20 | 0.89 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.89 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.89 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.89 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.89 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.89 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.89 |
| ▸ | RHOC | P08134 | 1/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.89 |
| ▸ | THRB | P10828 | 1/20 | 0.89 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.89 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.89 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.78 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.78 |
| ▸ | PDE6D | O43924 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bemfivastatin SCHEMBL18121688 | 1.00 | HMGCR (0.89) | HMGCRABCB11SLCO1B1HDAC1HDAC2 | |
| Bemfivastatin SCHEMBL517400 | 1.00 | HMGCR (0.89) | HMGCRABCB11SLCO1B1HDAC1HDAC2 | |
| Bemfivastatin SCHEMBL1900386 | 1.00 | HMGCR (0.89) | HMGCRABCB11SLCO1B1HDAC1HDAC2 | |
| Bemfivastatin SCHEMBL29441844 | 0.96 | ABCB11 (0.86) | HMGCRABCB11SLCO1B1HDAC1HDAC2 | |
| SCHEMBL28548478 | 0.95 | HMGCR (0.98) | HMGCRABCB11SLCO1B1HDAC1HDAC2 | |
| SCHEMBL6769237 | 0.95 | HMGCR (0.98) | HMGCRABCB11SLCO1B1HDAC1HDAC2 | |
| SCHEMBL13412147 | 0.95 | HMGCR (0.79) | HMGCRABCB11SLCO1B1HDAC1HDAC2 | |
| Atorvastatin SCHEMBL14645195 | 0.94 | HMGCR (0.97) | HMGCRABCB11SLCO1B1HDAC1HDAC2 | |
| SCHEMBL6761283 | 0.94 | HMGCR (0.97) | HMGCRABCB11SLCO1B1HDAC1HDAC2 | |
| Atorvastatin SCHEMBL4201645 | 0.94 | HMGCR (1.00) | HMGCRABCB11SLCO1B1HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114096523-A | Process for preparing (3R,5R) -7- (2- (4-fluorophenyl) -5-isopropyl-3-phenyl-4- ((4-hydroxymethylphenylamino) carbonyl) -pyrrol-1-yl) -3, 5-dihydroxyheptanoic acid hemicalcium salt and process for preparing intermediates used therein | 大元制药株式会社 | 2022-02-25 | — | — | CN | claimed |
| CN-112616314-A | Process for the preparation of (3R,5R) -7- [2- (4-fluorophenyl) -5-isopropyl-3-phenyl-4- [ (4-hydroxymethylphenylamino) carbonyl ] -pyrrol-1-yl ] -3, 5-dihydroxyheptanoic acid hemicalcium salt, intermediates therefor and process for the preparation of intermediates | 大元制药株式会社 | 2021-04-06 | — | — | CN | claimed |
| WO-2008020314-A2 | STATIN STABILIZING DOSAGE FORMULATIONS | RANBAXY LABORATORIES LIMITED (IN) | 2008-02-21 | — | — | WO | claimed |
| US-20070238716-A1 | STATIN STABILIZING DOSAGE FORMULATIONS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-11 | — | — | US | claimed |
| CN-114096523-A | Process for preparing (3R,5R) -7- (2- (4-fluorophenyl) -5-isopropyl-3-phenyl-4- ((4-hydroxymethylphenylamino) carbonyl) -pyrrol-1-yl) -3, 5-dihydroxyheptanoic acid hemicalcium salt and process for preparing intermediates used therein | 大元制药株式会社 | 2022-02-25 | — | — | CN | disclosed |
| CN-114096523-A | Process for preparing (3R,5R) -7- (2- (4-fluorophenyl) -5-isopropyl-3-phenyl-4- ((4-hydroxymethylphenylamino) carbonyl) -pyrrol-1-yl) -3, 5-dihydroxyheptanoic acid hemicalcium salt and process for preparing intermediates used therein | 大元制药株式会社 | 2022-02-25 | — | — | CN | disclosed |
| CN-114096523-A | Process for preparing (3R,5R) -7- (2- (4-fluorophenyl) -5-isopropyl-3-phenyl-4- ((4-hydroxymethylphenylamino) carbonyl) -pyrrol-1-yl) -3, 5-dihydroxyheptanoic acid hemicalcium salt and process for preparing intermediates used therein | 大元制药株式会社 | 2022-02-25 | — | — | CN | disclosed |
| CN-112616314-A | Process for the preparation of (3R,5R) -7- [2- (4-fluorophenyl) -5-isopropyl-3-phenyl-4- [ (4-hydroxymethylphenylamino) carbonyl ] -pyrrol-1-yl ] -3, 5-dihydroxyheptanoic acid hemicalcium salt, intermediates therefor and process for the preparation of intermediates | 大元制药株式会社 | 2021-04-06 | — | — | CN | disclosed |
| CN-112616314-A | Process for the preparation of (3R,5R) -7- [2- (4-fluorophenyl) -5-isopropyl-3-phenyl-4- [ (4-hydroxymethylphenylamino) carbonyl ] -pyrrol-1-yl ] -3, 5-dihydroxyheptanoic acid hemicalcium salt, intermediates therefor and process for the preparation of intermediates | 大元制药株式会社 | 2021-04-06 | — | — | CN | disclosed |
| CN-112616314-A | Process for the preparation of (3R,5R) -7- [2- (4-fluorophenyl) -5-isopropyl-3-phenyl-4- [ (4-hydroxymethylphenylamino) carbonyl ] -pyrrol-1-yl ] -3, 5-dihydroxyheptanoic acid hemicalcium salt, intermediates therefor and process for the preparation of intermediates | 大元制药株式会社 | 2021-04-06 | — | — | CN | disclosed |
| WO-2021010681-A2 | METHOD FOR PREPARING (3R,5R)-7-(2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-((4-HYDROXYMETHYLPHENYLAMINO)CARBONYL)-PYRROLE-1-YL)-3,5-DIHYDROXY HEPTANOIC ACID HEMICALCIUM SALT, AND METHOD FOR PREPARING INTERMEDIATES USED THEREIN | 대원제약주식회사 | 2021-01-21 | — | — | WO | disclosed |
| WO-2020040614-A1 | PREPARATION METHOD FOR (3R,5R)-7-[2-(4-FLUROPHENYL)-5-ISOPROPYL-3-PHENYL-4-[(4-HYDROXYMETHYLPHENYLAMINO)CARBONYL]-PYRRROL-1-YL]-3,5-DIHYDROXY HEPTANOIC ACID HEMICALCIUM SALT, INTERMEDIATE USED THEREFOR, AND PREPARATION METHOD FOR INTERMEDIATE | 대원제약주식회사 | 2020-02-27 | — | — | WO | disclosed |
| WO-2020040614-A1 | PREPARATION METHOD FOR (3R,5R)-7-[2-(4-FLUROPHENYL)-5-ISOPROPYL-3-PHENYL-4-[(4-HYDROXYMETHYLPHENYLAMINO)CARBONYL]-PYRRROL-1-YL]-3,5-DIHYDROXY HEPTANOIC ACID HEMICALCIUM SALT, INTERMEDIATE USED THEREFOR, AND PREPARATION METHOD FOR INTERMEDIATE | 대원제약주식회사 | 2020-02-27 | — | — | WO | disclosed |
| EP-1948598-A1 | PROCESS FOR PREPARATION OF (3R, 5R)-7-[2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-[(4-HYDROXY METHYL PHENYL AMINO) CARBONYL]-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT | RANBAXY LABORATORIES, LTD. (IN) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008020314-A2 | STATIN STABILIZING DOSAGE FORMULATIONS | RANBAXY LABORATORIES LIMITED (IN) | 2008-02-21 | — | — | WO | disclosed |
| US-20070238716-A1 | STATIN STABILIZING DOSAGE FORMULATIONS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-11 | — | — | US | disclosed |
| US-20070238716-A1 | STATIN STABILIZING DOSAGE FORMULATIONS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-11 | — | — | US | disclosed |
| US-20070238716-A1 | STATIN STABILIZING DOSAGE FORMULATIONS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-11 | — | — | US | disclosed |
| US-20070238716-A1 | STATIN STABILIZING DOSAGE FORMULATIONS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-11 | — | — | US | disclosed |
| WO-2007054790-A1 | PROCESS FOR PREPARATION OF (3R, 5R)-7-[2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-[(4-HYDROXY METHYL PHENYL AMINO) CARBONYL]-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT | RANBAXY LABORATORIES LIMITED (IN) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238716-A1 | STATIN STABILIZING DOSAGE FORMULATIONS | HMGCR, DHCR7, CYP46A1 | HMGCR 1/4885ABCB11 131/4885SLCO1B1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.